Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE:000403)
12.17
-0.11 (-0.90%)
Apr 29, 2026, 3:04 PM CST
SHE:000403 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Net Income | 353.42 | 419.54 | 745.32 | 612.11 | 587.13 | 391.06 | Upgrade
|
| Depreciation & Amortization | 142.13 | 142.13 | 127.14 | 145.47 | 126.39 | 115.76 | Upgrade
|
| Other Amortization | 9.27 | 9.27 | 8.75 | 0.65 | 4.43 | 7.39 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.76 | -0.76 | 0.12 | 0.54 | -0.44 | -0.27 | Upgrade
|
| Asset Writedown & Restructuring Costs | 96.51 | 96.51 | 3.46 | 1.29 | 3.59 | 103.67 | Upgrade
|
| Loss (Gain) From Sale of Investments | -8.95 | -8.95 | -24.12 | -17.56 | -7.97 | -77.91 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | -4.6 | -2.04 | 9.66 | 9.44 | Upgrade
|
| Other Operating Activities | -13.35 | -23.45 | -39.45 | -14.95 | -38.62 | -33.92 | Upgrade
|
| Change in Accounts Receivable | -472.67 | -472.67 | -131.42 | 274.65 | -329.07 | -196.58 | Upgrade
|
| Change in Inventory | -332.41 | -332.41 | -325.13 | -285.42 | 115.51 | 1.72 | Upgrade
|
| Change in Accounts Payable | -47.79 | -47.79 | -47.76 | -31.26 | 70.94 | 70.06 | Upgrade
|
| Change in Other Net Operating Assets | - | - | - | 2.23 | 10.6 | 21.65 | Upgrade
|
| Operating Cash Flow | -272 | -215.99 | 321.79 | 679.01 | 524.22 | 408.22 | Upgrade
|
| Operating Cash Flow Growth | - | - | -52.61% | 29.53% | 28.42% | 109.52% | Upgrade
|
| Capital Expenditures | -272.83 | -333.4 | -520.71 | -377.27 | -378.64 | -326.16 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.44 | 0.49 | 0.11 | 1.65 | 0.45 | 1.35 | Upgrade
|
| Cash Acquisitions | - | - | - | - | - | 64.57 | Upgrade
|
| Investment in Securities | 490 | 30 | 124.3 | 9.25 | -259.36 | -160 | Upgrade
|
| Other Investing Activities | -29.94 | 71.59 | 60.36 | 77.15 | 81.18 | -258.03 | Upgrade
|
| Investing Cash Flow | 187.66 | -231.32 | -335.94 | -289.21 | -556.38 | -678.28 | Upgrade
|
| Long-Term Debt Issued | - | 771.21 | 571.81 | 438.32 | 481.79 | 303.16 | Upgrade
|
| Total Debt Issued | 754.41 | 771.21 | 571.81 | 438.32 | 481.79 | 303.16 | Upgrade
|
| Long-Term Debt Repaid | - | -595.31 | -415.1 | -316.89 | -263.4 | -833.63 | Upgrade
|
| Total Debt Repaid | -621.3 | -595.31 | -415.1 | -316.89 | -263.4 | -833.63 | Upgrade
|
| Net Debt Issued (Repaid) | 133.12 | 175.9 | 156.72 | 121.43 | 218.39 | -530.47 | Upgrade
|
| Issuance of Common Stock | - | - | 14.22 | 8.3 | 2.51 | 1,597 | Upgrade
|
| Repurchase of Common Stock | - | - | - | -24.23 | -21.98 | - | Upgrade
|
| Common Dividends Paid | -274.47 | -273.8 | -264.63 | -66.79 | -49.66 | -12.05 | Upgrade
|
| Other Financing Activities | -5.28 | -5.6 | -0.06 | -0.47 | -0.8 | 1.76 | Upgrade
|
| Financing Cash Flow | -146.63 | -103.51 | -93.74 | 38.24 | 148.46 | 1,056 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.02 | 0.05 | -0.03 | -0.02 | -1.19 | -0.23 | Upgrade
|
| Net Cash Flow | -230.95 | -550.76 | -107.92 | 428.01 | 115.11 | 785.52 | Upgrade
|
| Free Cash Flow | -544.84 | -549.39 | -198.92 | 301.74 | 145.58 | 82.06 | Upgrade
|
| Free Cash Flow Growth | - | - | - | 107.27% | 77.41% | -46.94% | Upgrade
|
| Free Cash Flow Margin | -20.95% | -20.87% | -7.49% | 12.96% | 6.05% | 4.16% | Upgrade
|
| Free Cash Flow Per Share | -0.55 | -0.58 | -0.21 | 0.32 | 0.15 | 0.09 | Upgrade
|
| Cash Income Tax Paid | 242.87 | 217.87 | 252.75 | 213.87 | 172 | 148.92 | Upgrade
|
| Levered Free Cash Flow | -642.4 | -639.93 | -316.89 | 186.27 | -7.27 | -289.45 | Upgrade
|
| Unlevered Free Cash Flow | -642.4 | -639.93 | -310.22 | 192.28 | 0.25 | -282.71 | Upgrade
|
| Change in Working Capital | -850.27 | -850.27 | -494.83 | -46.5 | -159.95 | -107 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.